The Facts of Life..(1)
Buyouts and drug reps.
Sell the company to BP so we can get more drug reps, which will grow our scripts the man says.
Translation..I'm in the stock because I heard the company was getting bought out and I'm after some of that fast and easy money..
Facts..Buyouts are seldom telegraphed. Outsider knowledge can upset the balance of transactions. When you are hearing a company is in play, chances are most likely the story is a plant to get the PPS up so the big boys can distribute some stock to the gullible.
Amarin's script problem is not due to a paucity of drug reps..The drug reps we have now are not earning enough to pay their salaries. The problem is not with the reps, but with the fact the reps are being suffocated by the FDA policy that suppresses clinical information transfer from the company to the doctors the reps call on. Amarin's recent A1 victory hopefully will improve that situation. Without being able to explain to doctors why they should be using Vascepa, how can the drug reps be successful?
Understandably some of you easy money types that have bought in under $2 would be happy with a six dollar sell out...What happens then? Most of you are not savvy market players...if you were you would understand why Amarin is such a rare opportunity to make serious money, which will not happen with a quick single digit buyout. Patience is a very important quality if you plan on hanging around the stock market.
Vascepa (EPA) could become the most import commodity in health and medicine..That's what all those articles zum posts are suggesting..This is unique in my fifty years in the medical field...I have never seen anything that even comes close to the potential of this substance.
":>) JL
